PENDING TRANSACTIONS (Details) (Metronidazole 1.3%, USD $)	0 Months Ended
Apr. 30, 2013 Actavis Specialty Brands	Sep. 30, 2013 Medicis
Subsequent events
Sale price of worldwide rights	$ 55,000,000
Period of payment of minimum royalties from commercialization of development product	3 years
Acquired IPR&D		$ 66,600,000

Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant